GSA Capital Partners’s Orchestra BioMed OBIO Stock Holding History

GSA Capital Partners’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,773	Closed	-$45K	–	2038
2025 Q4	$45K	Buy	+10,773	New	+$43.5K	﹤0.01%	1578

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GSA Capital Partners's OBIO Position: Q1 2026 in Review

GSA Capital Partners sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 10,773 shares — an estimated $45K sold.

GSA Capital Partners first reported a position in OBIO in Q4 2025 and held it in 1 quarter. The position peaked at $45K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

GSA Capital Partners reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 10,773 Orchestra BioMed shares in Q1 2026, an estimated $45K.
GSA Capital Partners first reported a position in Orchestra BioMed in Q4 2025 and held it in 1 quarter.
GSA Capital Partners's Orchestra BioMed position peaked at $45K in Q4 2025.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.